| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
When LPS stimulation is applied to HL-60 cells and HUVECs, fuzapladib (IS-741) (1 μM, 3 h) can dramatically decrease labeling [3].
|
|---|---|
| ln Vivo |
Fuzapladib (IS-741) (po, 50 mg/kg, 7 days) effectively explains trinitrobenzene sulfonate (TNBS) ileitis by inhibiting the inflammatory response of circulating neutrophils [4].
|
| Animal Protocol |
Animal/Disease Models: Rat [4]
Doses: 50 mg/kg Route of Administration: Po; 7 days Experimental Results: Dramatically diminished rat ileal myeloperoxidase (MPO) activity and mucosal IL-8 levels, diminished polymorphonuclear cells and Infiltration of Mac-1 positive cells into inflammatory lesions effectively alleviates trinitrobenzene sulfonic acid (TNBS)-induced ileitis. |
| References | |
| Additional Infomation |
See also: IS-741 sodium (active moiety of).
|
| Molecular Formula |
C15H20F3N3O3S
|
|---|---|
| Molecular Weight |
379.3978
|
| Exact Mass |
379.118
|
| CAS # |
141283-87-6
|
| Related CAS # |
Fuzapladib sodium;141284-73-3
|
| PubChem CID |
154529
|
| Appearance |
White to off-white solid powder
|
| Density |
1.411g/cm3
|
| Index of Refraction |
1.548
|
| LogP |
5.184
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
557
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
TUWCZRFHNIOVTC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H20F3N3O3S/c1-2-25(23,24)21-13-12(8-11(9-19-13)15(16,17)18)20-14(22)10-6-4-3-5-7-10/h8-10H,2-7H2,1H3,(H,19,21)(H,20,22)
|
| Chemical Name |
N-[2-(ethylsulfonylamino)-5-(trifluoromethyl)pyridin-3-yl]cyclohexanecarboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~263.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6357 mL | 13.1787 mL | 26.3574 mL | |
| 5 mM | 0.5271 mL | 2.6357 mL | 5.2715 mL | |
| 10 mM | 0.2636 mL | 1.3179 mL | 2.6357 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
